Colhoun, H. M., Robinson, J. G., Farnier, M., Cariou, B., Blom, D., Kereiakes, D. J., . . . Chaudhari, U. (2014). Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: Rationale and design of the ODYSSEY COMBO I and II trials. BioMed Central.

Colhoun, Helen M., Jennifer G. Robinson, Michel Farnier, Bertrand Cariou, Dirk Blom, Dean J. Kereiakes, Christelle Lorenzato, Robert Pordy, و Umesh Chaudhari. Efficacy and Safety of Alirocumab, a Fully Human PCSK9 Monoclonal Antibody, in High Cardiovascular Risk Patients With Poorly Controlled Hypercholesterolemia On Maximally Tolerated Doses of Statins: Rationale and Design of the ODYSSEY COMBO I and II Trials. BioMed Central, 2014.

Colhoun, Helen M., et al. Efficacy and Safety of Alirocumab, a Fully Human PCSK9 Monoclonal Antibody, in High Cardiovascular Risk Patients With Poorly Controlled Hypercholesterolemia On Maximally Tolerated Doses of Statins: Rationale and Design of the ODYSSEY COMBO I and II Trials. BioMed Central, 2014.